Uniphar (LON:UPR) Given “Buy” Rating at Shore Capital

Shore Capital reaffirmed their buy rating on shares of Uniphar (LON:UPR) in a report issued on Tuesday morning, MarketBeat.com reports.

Uniphar Stock Performance

Shares of UPR opened at GBX 195 ($2.43) on Tuesday. The company has a quick ratio of 0.60, a current ratio of 0.90 and a debt-to-equity ratio of 119.43. The business has a 50-day simple moving average of GBX 174.62 and a two-hundred day simple moving average of GBX 198.80. The stock has a market cap of £532.39 million, a price-to-earnings ratio of 1,392.86 and a beta of 0.75. Uniphar has a 52 week low of GBX 163 ($2.03) and a 52 week high of GBX 256 ($3.19).

Uniphar Company Profile

Headquartered in Dublin, Ireland Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology
manufacturers across three divisions – Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK and the Benelux.